Skip to main content

DermTech, Inc. (DMTK)

NASDAQ: DMTK · IEX Real-Time Price · USD
36.69 1.75 (5.01%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap1.09B
Revenue (ttm)9.13M
Net Income (ttm)-51.00M
Shares Out29.61M
EPS (ttm)-2.15
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume806,476
Open35.11
Previous Close34.94
Day's Range34.63 - 36.74
52-Week Range9.85 - 84.49
Beta0.71
AnalystsStrong Buy
Price Target62.00 (+69.0%)
Est. Earnings DateNov 3, 2021

About DMTK

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th...

IndustryBiotechnology
Employees114
Stock ExchangeNASDAQ
Ticker SymbolDMTK
Full Company Profile

Financial Performance

In 2020, DermTech's revenue was $5.89 million, an increase of 74.94% compared to the previous year's $3.36 million. Losses were -$35.25 million, 79.0% more than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for DermTech stock is "Strong Buy." The 12-month stock price forecast is 62.00, which is an increase of 68.98% from the latest price.

Price Target
$62.00
(68.98% upside)
Analyst Consensus: Strong Buy

News

How DermTech Could Change Skin Cancer Testing -- Or Fizzle Out

DermTech's innovative skin treatment is making it easier and cheaper to test for skin cancer, causing the business to grow. Fast.

3 days ago - The Motley Fool

DermTech Study, “Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic...

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that SKIN: The Journal ...

3 days ago - Business Wire

Should Investors Be Concerned About DermTech?

Be concerned? No. Be patient?

5 days ago - The Motley Fool

3 Monster Stocks in the Making to Buy Right Now

Their growth prospects are massive.

Other symbols:GRTSMTTR
5 days ago - The Motley Fool

DermTech Management to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management wil...

1 week ago - Business Wire

3 Growth Stocks Under $50 That Could Double Your Money

You won't need much upfront cash to buy these promising growth stocks.

Other symbols:SOFI
1 week ago - The Motley Fool

DermTech to Present at Florida Association of Health Plans 2021 Annual Conference

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it is presenting at the...

2 weeks ago - Business Wire

DermTech Management to Participate at the Lake Street 2021 BIG5 Conference

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management wil...

2 weeks ago - Business Wire

Got $100? 3 Smart Growth Stocks to Buy Right Now

A C-note will allow you to pick up shares of all three of these great stocks.

Other symbols:BEP
2 weeks ago - The Motley Fool

Why Shares of DermTech Dropped 19% in July

The company's noninvasive skin genomics platform has great potential, but its losses have made investors wary.

1 month ago - The Motley Fool

DermTech, Inc. (DMTK) Reports Q2 Loss, Tops Revenue Estimates

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 11.11% and 11.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Recap: DermTech Q2 Earnings

Shares of DermTech (NASDAQ:DMTK) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 1.72% over the past year to ($0.59), which missed the estim...

1 month ago - Benzinga

DermTech Reports Second Quarter 2021 Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported unaudited financial resu...

1 month ago - Business Wire

Will DermTech, Inc. (DMTK) Report Negative Earnings Next Week? What You Should Know

DermTech, Inc. (DMTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

DermTech to Announce Second Quarter Financial Results on August 4, 2021

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it plans to release its...

1 month ago - Business Wire

DermTech Announces New San Diego Headquarters

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced expansion pl...

1 month ago - Business Wire

3 Healthcare Stocks That Could Make You Rich

They're disruptors that could change healthcare.

Other symbols:BEAMNNOX
1 month ago - The Motley Fool

$10,000 Invested in These Growth Stocks Could Make You a Fortune Over the Next 10 Years

All three of them are well-positioned for tremendous growth.

Other symbols:ETSYNVDA
1 month ago - The Motley Fool

This Medical Device Company Is Changing the Game in Skin Cancer

And it's on sale right now.

1 month ago - The Motley Fool

DermTech Announces New Appointment of Monica Tellado to its Board of Directors

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the appointment of Moni...

2 months ago - Business Wire

DermTech CEO John Dobak, M.D. Wins San Diego Business Journal CEO of the Year Award, Public Company, Medium Category

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that DermTech CEO, John...

2 months ago - Business Wire

Ditch Dogecoin: These 3 Stocks Could Double Your Money

The path to a twofold or greater return is straightforward for each of these stocks.

Other symbols:AXSM
2 months ago - The Motley Fool

DermTech to Partner with University of Barcelona for Research Study on Atopic Dermatitis and Psoriasis

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today a collaboration with re...

2 months ago - Business Wire

DermTech Announces Three New Key Leadership Appointments: Chief Medical Officer, Vice President, Sales and Vice Presi...

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today three new key leadershi...

3 months ago - Business Wire

DermTech Announces Three New Scientific Advisory Board Members

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the additions of Dr. Kl...

3 months ago - Business Wire